After a heart attack, evolocumab lowers LDL further in a small 12-week trial

A comparison after a heart attack treated with angioplasty

The researchers studied patients who had experienced an ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. This single-center, open-label trial compared atorvastatin alone with atorvastatin plus evolocumab, with 45 patients in each group.

The comparator treatment was atorvastatin at 20 mg per day, described by the authors as moderate-intensity. This detail matters: the study does not directly address the additional benefit of evolocumab when standard treatment already includes a high-intensity statin.

Follow-up lasted 12 weeks. One patient in the combination group withdrew on day 28. Their last available observation was used to replace missing data at the end of follow-up.

An additional reduction in LDL, not proof of recovery

The primary endpoint was the change in LDL. The adjusted mean difference between groups was −0.31 mmol/L in favor of the combination, with a 95% confidence interval ranging from −0.60 to −0.02 mmol/L. Considerable uncertainty therefore remains about the size of this effect.

The proportion of patients achieving an LDL level below 1.4 mmol/L was 48.89% with the combination, compared with 22.2% with atorvastatin alone. This threshold is presented in the abstract as the recommended target. Reaching it is a lipid outcome, not a demonstration of fewer recurrent heart attacks or lower mortality in this trial.

No significant difference between groups was observed in the cardiac function measures assessed. The abstract therefore does not support a claim that the combination improves heart recovery.

Interesting but exploratory markers

The authors report favorable changes in nitric oxide, endothelin-1 and sICAM-1, as well as a reduction in IL-6. These measurements provide information about certain aspects of vascular function and inflammation, but do not, on their own, constitute evidence of clinical benefit.

All secondary analyses were exploratory, with no correction for multiple comparisons. This increases the possibility that some statistically significant findings were due to chance.

No significant difference in adverse events was detected. With this small sample and short follow-up, this does not demonstrate equivalent long-term safety. The authors call for confirmation in larger trials using a high-intensity statin as standard treatment.

What we can take away

This trial supports an additional reduction in LDL when evolocumab is added after a heart attack, compared with moderate-intensity atorvastatin. It demonstrates neither better cardiac recovery nor a reduction in cardiovascular events.